Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
== Pharmacokinetics == Applicable pharmacokinetic indexes are free azalide AUC24/MIC because of the post antibiotic effect they exhibit, and free azalide concentration/MIC. Due to their large volume of distribution and lipophilic structure, azalides concentrate effectively in tissue.
All the secondary ions generated in SIMS analysis originate from the topmost monolayers of the bombarded solid. This means that all different modes of SIMS analysis are basically surface analysis; secondary-ion emissions—atomic as well as molecular—reflect the chemical composition of the near-surface region of the bombarded solid. However, the intention of different SIMS analyses may be quite different. This depends on the erosion rate of the surface, which is controlled by the dose of the primary ions. It may be bulk analysis (dynamic SIMS) or a true analysis of originally uppermost monolayer of a condensed phase (static SIMS).
=== Animals === For mice, the dose at which acute toxicity occurs for intravenous administration is 40 mg/kg and for subcutaneous injection (injection in the layer of skin directly below the dermis and epidermis) this is 380 mg/kg. The lethal dose of dimethocaine for a mouse is 0.3 g per kilogram body weight. An abdominal constriction test was performed in mice, using doses of 5, 10, and 20 mg/kg of dimethocaine which were administered subcutaneously. This test showed induced dose-dependent antinociceptive responses, which are processes that block detection of a painful or injurious stimulus by sensory neurons. Impairment of memory processes was found to be a toxic effect in the elevated plus-maze test in mice.
Bean chips are chips prepared using beans as a primary ingredient. Bean chips have been described as being higher in fiber and protein compared to corn and potato chips. Bean chips may be prepared from a variety of bean types and rice, such as brown rice, pinto beans, black beans, and white beans. Some bean chips are prepared using green beans. They may be prepared from a bean dough that is steamed, sliced, and fried. They may be consumed as a snack food and may be accompanied by various dips.
== History == The chain was founded in Eugene by Ron Fraedrick (1928–2015), who opened the first restaurant near his alma mater, the University of Oregon, at 13th Avenue and High Street in January 1960. In 1962, the first Taco Time franchise opened in White Center, Washington. In the 1970s, the company expanded to 48 restaurants in seven Western states. In 1978, the company franchised its first international restaurant in Lethbridge, Alberta, Canada. In 1979, Taco Time Northwest became a licensee with the rights to franchise and operate the Taco Time concept independently. Taco Time Northwest's operating region includes western Washington from Longview to the Canada–United States border and the eastern Washington cities of Wenatchee and Moses Lake. In 1984, food at a location in The Dalles was allegedly poisoned by members of the Rajneesh movement in a bioterror attack. Taco Time has since expanded, now holding more than 300 franchises in the United States and Canada. They previously had locations in Kuwait, Greece, and Netherlands Antilles (Curaçao) which seem to have closed. In 2003, the company was bought by Kahala Brands of Scottsdale, Arizona.
Sources: en.wikipedia.org
The endoplasmic reticulum does not harbor an ATP-regeneration machinery, and therefore requires ATP import from mitochondria. The imported ATP is vital for the ER to carry out its house keeping cellular functions, such as for protein folding and trafficking. The ER ATP transporter, SLC35B1/AXER, was recently cloned and characterized, and the mitochondria supply ATP to the ER through a Ca2+-antagonized transport into the ER (CaATiER) mechanism. The CaATiER mechanism shows sensitivity to cytosolic Ca2+ ranging from high nM to low μM range, with the Ca2+-sensing element yet to be identified and validated.
Radon was discovered in 1899 by Ernest Rutherford and Robert B. Owens at McGill University in Montreal. It was the fifth radioactive element to be discovered, after uranium, thorium, radium, and polonium. In 1899, Pierre and Marie Curie observed that the gas emitted by radium remained radioactive for a month. Later that year, Rutherford and Owens noticed variations when trying to measure radiation from thorium oxide. Rutherford noticed that the compounds of thorium continuously emit a radioactive gas that remains radioactive for several minutes, and called this gas "emanation" (from Latin: emanare, to flow out, and emanatio, expiration), and later "thorium emanation" ("Th Em"). In 1900, Friedrich Ernst Dorn reported some experiments in which he noticed that radium compounds emanate a radioactive gas he named "radium emanation" ("Ra Em"). In 1901, Rutherford and Harriet Brooks demonstrated that the emanations are radioactive, but credited the Curies for the discovery of the element. In 1903, similar emanations were observed from actinium by André-Louis Debierne, and were called "actinium emanation" ("Ac Em"). Several shortened names were soon suggested for the three emanations: exradio, exthorio, and exactinio in 1904; radon (Ro), thoron (To), and akton or acton (Ao) in 1918; radeon, thoreon, and actineon in 1919, and eventually radon, thoron, and actinon in 1920.
=== Variable volume reactions === In some reactions the reactants and the products have significantly different densities. Consequently, as the reaction proceeds the volume of the reaction changes. This variable volume adds terms to the design equations. Taking this volume change into consideration the volume of the reaction becomes:
Born a British citizen of an Iraqi Jewish German Jewish mother and British father, she now holds joint citizenship after she took United States citizenship in 2005, following her emigration in 1984 to edit Vanity Fair. Alex Brummer (born 25 May 1949); author of eight books; writes for Jewish News, Times of Israel, city editor of the Daily Mail; financial editor of The Guardian; regular contributor to The Jewish Chronicle writing on business, media, the Holocaust, Middle East policy; also writes "The Money" article for the New Statesman; member of editorial board of Jewish Renaissance magazine; Vice-president of the Board of Deputies of British Jews; covered the 1980, 1984, and 1988 US presidential elections for The Guardian and won the 1989 Overseas Press Club award for best foreign correspondent in the US; worked as editor for the Financial Mail on Sunday; voted Financial Journalist of the Year at the British Press Awards; covered the 2003 Iraq War for the Daily Mail from Washington, D.C.; led the newspaper's coverage on the 2007 run on Northern Rock, collapse of Lehman Brothers, and subsequent credit crunch. In 2009, Brummer appeared as witness at House of Commons Treasury Select Committee to answer questions on role of media in financial stability and "whether financial journalists should operate under any form of reporting restrictions during banking crises".
== Medical uses == For over 90 years, hematopoietic stem cell transplantation (HSCT) has been used to treat people with conditions such as leukemia and lymphoma; this is the only widely practiced form of stem-cell therapy. During chemotherapy, most growing cells are killed by the cytotoxic agents. These agents, however, cannot discriminate between the leukaemia or neoplastic cells, and the hematopoietic stem cells within the bone marrow. This is the side effect of conventional chemotherapy strategies that the stem-cell transplant attempts to reverse; a donor's healthy bone marrow reintroduces functional stem cells to replace the cells lost in the host's body during treatment. The transplanted cells also generate an immune response that helps to kill off the cancer cells; this process can go too far, however, leading to graft vs host disease, the most serious side effect of this treatment. Another stem-cell therapy called Prococvhymal, was conditionally approved in Canada in 2012 for the management of acute graft-vs-host disease in children who are unresponsive to steroids. It is an allogenic stem therapy based on mesenchymal stem cells (MSCs) derived from the bone marrow of adult donors. MSCs are purified from the marrow, cultured and packaged, with up to 10,000 doses derived from a single donor. The doses are stored frozen until needed. The FDA has approved five hematopoietic stem-cell products derived from umbilical cord blood, for the treatment of blood and immunological diseases.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.